SEATTLE, Nov. 18, 2011 (GLOBE NEWSWIRE) -- Attorney Advertising. Keller Rohrback L.L.P. (www.krclassaction.com) is investigating the claims of women who have suffered severe side effects and no benefit from the use of Avastin in the treatment of metastatic breast cancer. The U.S. Food and Drug Administration ("FDA") Commissioner recently revoked the approval of Avastin for treatment of this particular type of breast cancer in the United States. The FDA Commissioner stated: "After reviewing the available studies, it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks. Nor is there evidence that use of Avastin will help them live longer or improve their quality of life." Avastin is manufactured by Genentech, Inc., a member of the Roche Group.
If you or someone you know were prescribed Avastin as part of your treatment plan for metastatic breast cancer, or you would like more information regarding our investigation, please contact attorneys Mike Woerner or Mark Samson at (800) 776-6044 or via email at consumer@kellerrohrback.com.
Keller Rohrback, with offices in Seattle, Phoenix, New York and Santa Barbara is proud to offer its expertise in personal injury cases to clients nationwide.
Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.